{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:28:09Z","timestamp":1793600889894,"version":"4.5.0"},"reference-count":212,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaad.2024.10.130","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:19:03Z","timestamp":1740136743000},"page":"21-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Minimally invasive modalities for keratinocyte carcinomas \u2014Part II: Treatment"],"prefix":"10.1016","volume":"95","author":[{"given":"Nathan","family":"Gasek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-9825","authenticated-orcid":false,"given":"Albert E.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gronbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelesh P.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Balboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"McMullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Skudalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-6159","authenticated-orcid":false,"given":"Jonas A.","family":"Adalsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jaad.2024.10.130_bib1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.6004\/jnccn.2023.0056","article-title":"Basal cell skin cancer, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schmults","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.jaad.2024.10.130_bib2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.6004\/jnccn.2021.0059","article-title":"NCCN guidelines\u00ae insights: squamous cell skin cancer, version 1.2022: featured updates to the NCCN guidelines","volume":"19","author":"Schmults","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.jaad.2024.10.130_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1524-4725.1991.tb03425.x","article-title":"Recurrence rates of treated basal cell carcinomas: Part 2: curettage-electrodesiccation","volume":"17","author":"Silverman","year":"1991","journal-title":"J Dermatol Surg Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2024.10.130_bib4","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/DSS.0000000000003855","article-title":"Electrodesiccation and curettage for squamous cell carcinoma in situ: the effect of anatomic location on local recurrence","volume":"49","author":"Veverka","year":"2023","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib5","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jid.2012.403","article-title":"Tumor recurrence 5 Years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"133","author":"Chren","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Kim","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2006.07.007","article-title":"Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation","volume":"56","author":"Rodriguez-Vigil","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/dsu.12122","article-title":"Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone","volume":"39","author":"Blixt","year":"2013","journal-title":"Dermatol Surg"},{"issue":"nov04 1","key":"10.1016\/j.jaad.2024.10.130_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f6153","article-title":"Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies","volume":"347","author":"Lansbury","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1046\/j.1365-2133.2001.04141.x","article-title":"Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial","volume":"144","author":"Wang","year":"2001","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.10.130_bib11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/DSS.0000000000001106","article-title":"Pulsed CO2 laser ablation of superficial basal cell of limbs and trunk: a comparative randomized clinical trial with cryotherapy and surgical ablation","volume":"43","author":"Zane","year":"2017","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib12","first-page":"547","article-title":"Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial","volume":"18","author":"Basset-Seguin","year":"2008","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib13","first-page":"579","article-title":"Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma","volume":"33","author":"Kuijpers","year":"2007","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaad.2021.07.067","article-title":"Efficacy of nonexcisional treatment modalities for superficially invasive and in situ squamous cell carcinoma: a systematic review and meta-analysis","volume":"87","author":"Stewart","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/1203475420943258","article-title":"Prospective clinical trial comparing curettage and cryosurgery to curettage and electrodesiccation in the management of minimally invasive basal and squamous cell carcinomas","volume":"24","author":"Fournier","year":"2020","journal-title":"J Cutan Med Surg"},{"issue":"9","key":"10.1016\/j.jaad.2024.10.130_bib16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-4632.2011.04969.x","article-title":"Prospective trial of curettage and cryosurgery in the management of non-facial, superficial, and minimally invasive basal and squamous cell carcinoma","volume":"50","author":"Peikert","year":"2011","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/146288301753377852","article-title":"Treatment of common warts and actinic keratoses by Er:YAG laser","volume":"3","author":"Wollina","year":"2001","journal-title":"J Cutan Laser Ther"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib18","first-page":"909","article-title":"Superpulsed CO2 laser treatment of basal cell carcinoma with intraoperatory histopathologic and cytologic examination","volume":"28","author":"Campolmi","year":"2002","journal-title":"Dermatol Surg"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/DSS.0000000000001048","article-title":"An analysis of laser therapy for the treatment of nonmelanoma skin cancer","volume":"43","author":"Soleymani","year":"2017","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40257-020-00562-8","article-title":"Laser treatment for non-melanoma skin cancer: a systematic review and meta-analysis","volume":"22","author":"Sharon","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/12034754211027515","article-title":"Laser resurfacing monotherapy for the treatment of actinic keratosis","volume":"25","author":"Tai","year":"2021","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/lsm.20048","article-title":"Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury","volume":"34","author":"Manstein","year":"2004","journal-title":"Lasers Surg Med"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2008.01.003","article-title":"The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing","volume":"58","author":"Alexiades-Armenakas","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib24","first-page":"1099","article-title":"Treatment of actinic keratosis: a systematic review","volume":"315","author":"Worley","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/DSS.0000000000003672","article-title":"Nonablative fractional laser treatment is associated with a decreased risk of subsequent facial keratinocyte carcinoma development","volume":"49","author":"Benson","year":"2023","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2024.10.130_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/286480","article-title":"Treatment of basal cell carcinomas with pulsed dye laser: a case series","volume":"2012","author":"Minars","year":"2012","journal-title":"J Skin Cancer"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/GOX.0000000000004850","article-title":"Pulsed dye laser for treatment of basal cell carcinoma","volume":"11","author":"Baran","year":"2023","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/lsm.21035","article-title":"Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12\u201321 months after treatment","volume":"43","author":"Konnikov","year":"2011","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.jaad.2024.10.130_bib29","first-page":"309","article-title":"A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy","volume":"179","author":"Morton","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2013.02.014","article-title":"Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up","volume":"69","author":"Roozeboom","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1365-2133.2008.08787.x","article-title":"Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial","volume":"159","author":"Mosterd","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2133.2007.07996.x","article-title":"A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma","volume":"157","author":"Berroeta","year":"2007","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/bjd.15967","article-title":"Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial","volume":"178","author":"Kessels","year":"2018","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib34","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1046\/j.1365-2133.2000.04000.x","article-title":"Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy","volume":"143","author":"Haller","year":"2000","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib35","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/jocd.12236","article-title":"Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis","volume":"15","author":"Zou","year":"2016","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40257-023-00829-w","article-title":"Photodynamic therapy in treating a subset of basal cell carcinoma: strengths, shortcomings, comparisons with surgical modalities, and potential role as adjunctive therapy","volume":"25","author":"Chen","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib37","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdv.12031","article-title":"European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications \u2013 actinic keratoses, Bowen's disease, basal cell carcinoma","volume":"27","author":"Morton","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2024.10.130_bib38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/archderm.134.7.821","article-title":"Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical \u03b4-aminolevulinic acid photodynamic therapy","volume":"134","author":"Fink-Puches","year":"1998","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib39","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1159\/000524745","article-title":"Long-term efficacy of photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus conventional two-stage topical methyl aminolevulinate for superficial basal-cell carcinoma","volume":"238","author":"Van Delft","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2024.10.130_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2019.101644","article-title":"Topical 5-aminolevulinic acid-mediated photodynamic therapy for basal cell carcinoma","volume":"30","author":"Filonenko","year":"2020","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4103\/0019-5154.113968","article-title":"Aminolevulinic acid-photodynamic therapy of basal cell carcinoma and factors affecting the response to treatment: a clinical trial","volume":"58","author":"Tehranchinia","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"1-2","key":"10.1016\/j.jaad.2024.10.130_bib42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1615\/JEnvironPatholToxicolOncol.v25.i1-2.260","article-title":"Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery","volume":"25","author":"Thompson","year":"2006","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib43","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1365-2133.2012.10878.x","article-title":"High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study: prospective 10-year follow-up study of PDT in BCC","volume":"166","author":"Christensen","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/1011-1344(95)90253-8","article-title":"Repetitive photodynamic therapy with topical \u03b4-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours","volume":"29","author":"Calzavara-Pinton","year":"1995","journal-title":"J Photochem Photobiol B"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib45","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaad.2019.10.079","article-title":"Photodynamic therapy for cutaneous squamous cell carcinoma in situ: impact of anatomic location, tumor diameter, and incubation time on effectiveness","volume":"82","author":"Kibbi","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/028418600750013285","article-title":"Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid","volume":"39","author":"Soler","year":"2000","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2024.10.130_bib47","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jdv.16017","article-title":"European Dermatology Forum guidelines on topical photodynamic therapy 2019 part 1: treatment delivery and established indications \u2013 actinic keratoses, Bowen's disease and basal cell carcinomas","volume":"33","author":"Morton","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2024.10.130_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pdpdt.2018.02.009","article-title":"Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: a bilaterally controlled comparison study","volume":"22","author":"Maytin","year":"2018","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13555-023-00888-1","article-title":"Advances in photodynamic therapy for the treatment of actinic keratosis and nonmelanoma skin cancer: a narrative review","volume":"13","author":"Farberg","year":"2023","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib50","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/bjd.13138","article-title":"Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial","volume":"171","author":"Rubel","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/jdv.12076","article-title":"Daylight-mediated photodynamic therapy of basal cell carcinomas \u2013 an explorative study","volume":"28","author":"Wiegell","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/DSS.0000000000000633","article-title":"Daylight photodynamic therapy: what is known and what is yet to Be determined","volume":"42","author":"Fitzmaurice","year":"2016","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib53","doi-asserted-by":"crossref","first-page":"adv00358","DOI":"10.2340\/00015555-3690","article-title":"Systematic literature review and network meta-analysis of the efficacy and acceptability of interventions in actinic keratoses","volume":"101","author":"Ezzedine","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/120347540500900501","article-title":"Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies","volume":"9","author":"Gupta","year":"2005","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2024.10.130_bib55","article-title":"Interventions for actinic keratoses","volume":"12","author":"Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12822","article-title":"Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: a network meta-analysis","volume":"32","author":"Wu","year":"2019","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib57","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/jdv.15459","article-title":"Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis","volume":"33","author":"Heppt","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjd.17148","article-title":"Local interventions for actinic keratosis in organ transplant recipients: a systematic review","volume":"180","author":"Heppt","year":"2019","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.10.130_bib59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.7326\/M18-0678","article-title":"Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis","volume":"169","author":"Drucker","year":"2018","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.jaad.2024.10.130_bib60","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/09546634.2019.1638883","article-title":"Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial","volume":"31","author":"Jia","year":"2020","journal-title":"J Dermatol Treat"},{"issue":"12","key":"10.1016\/j.jaad.2024.10.130_bib61","first-page":"1","article-title":"Interventions for basal cell carcinoma of the skin Cochrane Skin Group","volume":"2020","author":"Thomson","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib62","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2133.2012.11061.x","article-title":"Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials: overall treatment success in primary superficial basal cell carcinoma","volume":"167","author":"Roozeboom","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib63","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jaad.2006.01.055","article-title":"Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial","volume":"54","author":"Patel","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib64","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archderm.142.6.729","article-title":"Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial","volume":"142","author":"Morton","year":"2006","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaad.2023.08.076","article-title":"Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: a multicenter randomized controlled trial","volume":"90","author":"Ahmady","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib66","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2021.08.045","article-title":"Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: a retrospective cohort analysis","volume":"87","author":"Neale","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib67","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/ijd.14106","article-title":"Topical 5-fluorouracil in dermatologic disease","volume":"57","author":"Prince","year":"2018","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib68","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s40800-017-0068-6","article-title":"Life-threatening reaction with topical 5-fluorouracil","volume":"5","author":"Kishi","year":"2018","journal-title":"Drug Saf Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib69","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI89820","article-title":"Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy","volume":"127","author":"Cunningham","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib70","doi-asserted-by":"crossref","first-page":"60","DOI":"10.36849\/JDD.6632","article-title":"Use of topical calcipotriol plus 5-fluorouracil in the treatment of actinic keratosis: a systematic review","volume":"21","author":"Mohney","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib71","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2133.2003.05033.x","article-title":"Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease","volume":"148","author":"Salim","year":"2003","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib72","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jid.2017.09.033","article-title":"Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma","volume":"138","author":"Jansen","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2024.10.130_bib73","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/ijd.13235","article-title":"Imiquimod in dermatology: an overview","volume":"55","author":"Hanna","year":"2016","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib74","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib75","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib76","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2024.10.130_bib77","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/archdermatol.2009.291","article-title":"Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review","volume":"145","author":"Love","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib78","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jdin.2022.01.010","article-title":"Local skin reactions and the onset of influenza-like signs and symptoms induced by imiquimod","volume":"7","author":"Bhatia","year":"2022","journal-title":"JAAD Int"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib79","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1365-2133.2005.06486.x","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe","volume":"152","author":"Schulze","year":"2005","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.10.130_bib80","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archderm.138.9.1165","article-title":"Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens","volume":"138","author":"Shumack","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib81","first-page":"39","article-title":"Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream","volume":"4","author":"Zeichner","year":"2011","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib82","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13356","article-title":"Clinical evaluation and efficacy of Imiquimod 3.75% cream for the treatment of actinic keratosis, pigmented basal cell carcinomas, and actinic cheilitis","volume":"33","author":"Paolino","year":"2020","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib83","first-page":"600","article-title":"Diclofenac sodium 3% gel for the management of actinic keratosis: 10+ years of cumulative evidence of efficacy and safety","volume":"11","author":"Martin","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib84","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2230.2010.03999.x","article-title":"Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses","volume":"36","author":"Akarsu","year":"2011","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/jdv.15868","article-title":"Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials","volume":"34","author":"Gollnick","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib86","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1590\/abd1806-4841.20132083","article-title":"Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil","volume":"88","author":"Segatto","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.10.130_bib87","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib88","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaad.2016.01.050","article-title":"The effect of topical diclofenac 3% and calcitriol 3 \u03bcg\/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): a phase II, randomized controlled trial","volume":"75","author":"Brinkhuizen","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib89","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 trials of tirbanibulin ointment for actinic keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jaad.2024.10.130_bib90","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ced\/llad271","article-title":"Tirbanibulin: an alternative topical approach to manage superficial basal cell carcinoma. Comment on: \u2018Successful treatment of field cancerization on the dorsum of the hands with 1% tirbanibulin ointment\u2019","volume":"48","author":"Martora","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdcr.2022.07.035","article-title":"Rapid resolution of recalcitrant basal cell carcinoma of the ear with topical tirbanibulin","volume":"28","author":"Moore","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib92","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaad.2022.04.013","article-title":"Focused update: guidelines of care for the management of actinic keratosis","volume":"87","author":"Eisen","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0190-9622(97)70328-1","article-title":"Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil\/epinephrine injectable gel","volume":"36","author":"Miller","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib94","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2015.09.040","article-title":"Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): a review","volume":"74","author":"Metterle","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib95","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jaad.2020.12.049","article-title":"Intralesional 5-fluorouracil for the treatment of squamous cell carcinomas","volume":"84","author":"Maxfield","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib96","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0190-9622(80)80007-7","article-title":"Successful treatment of keratoacanthoma with intralesional fluorouracil","volume":"2","author":"Goette","year":"1980","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib97","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.abd.2022.09.009","article-title":"Chemotherapeutical treatment of basal cell carcinoma with bleomycin via microinfusion of the drug into the skin (MMP\u00ae)","volume":"98","author":"Pacola","year":"2023","journal-title":"An Bras Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib98","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejso.2019.11.509","article-title":"Electrochemotherapy for the treatment of primary basal cell carcinoma; A randomised control trial comparing electrochemotherapy and surgery with five year follow up","volume":"46","author":"Clover","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib99","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0190-9622(97)70178-6","article-title":"Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma","volume":"37","author":"Glass","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.05.001","article-title":"European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: results of the treatment of skin cancer","volume":"63","author":"Bertino","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib101","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2133.1983.tb04619.x","article-title":"Treatment of keratoacanthoma with intralesional bleomycin","volume":"109","author":"Sayama","year":"1983","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib102","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s13555-020-00400-z","article-title":"Intralesional methotrexate for the treatment of advanced keratinocytic tumors: a multi-center retrospective study","volume":"10","author":"Gualdi","year":"2020","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.jaad.2024.10.130_bib103","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/09546634.2018.1451817","article-title":"Treatment of basal cell carcinoma: is intralesional methotrexate an option?","volume":"29","author":"Balighi","year":"2018","journal-title":"J Dermatol Treat"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib104","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15315","article-title":"Clinicopathological evaluation of intralesional methotrexate in different subtypes of basal cell carcinoma","volume":"35","author":"Khashaba","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib105","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14377","article-title":"Histological findings after intralesional methotrexate treatment in cutaneous squamous cell carcinoma","volume":"33","author":"Berg\u00f3n-Send\u00edn","year":"2020","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.jaad.2024.10.130_bib106","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ad.2011.03.013","article-title":"Intralesional infusion of methotrexate as neoadjuvant therapy improves the cosmetic and functional results of surgery to treat keratoacanthoma: results of a randomized trial","volume":"102","author":"Martorell-Calatayud","year":"2011","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas Engl Ed"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib107","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/0190-9622(90)70276-N","article-title":"Intralesional interferon therapy for basal cell carcinoma","volume":"23","author":"Cornell","year":"1990","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib108","first-page":"214","article-title":"Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma","volume":"190","author":"Chimenti","year":"1995","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.jaad.2024.10.130_bib109","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1001\/archderm.1992.01680210064008","article-title":"Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy","volume":"128","author":"Edwards","year":"1992","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4103\/0974-9233.167822","article-title":"Intralesional bleomycin as an adjunct therapeutic modality in eyelid and extraocular malignancies and tumors","volume":"22","author":"Meyer","year":"2015","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib111","doi-asserted-by":"crossref","first-page":"192","DOI":"10.36849\/JDD.5518","article-title":"Intralesional 5-fluorouracil for treatment of non-melanoma skin cancer: a systematic review","volume":"20","author":"Maghfour","year":"2021","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib112","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0190-9622(98)70502-X","article-title":"Intratumoral chemotherapy with fluorouracil\/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma","volume":"38","author":"Kraus","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib113","series-title":"StatPearls","article-title":"Bleomycin","author":"Brandt","year":"2023"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib114","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaad.2009.09.048","article-title":"Intralesional chemotherapy for nonmelanoma skin cancer: a practical review","volume":"63","author":"Kirby","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.10.130_bib115","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/0284186X.2018.1454602","article-title":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","volume":"57","author":"Gehl","year":"2018","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib116","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaad.2020.02.018","article-title":"Efficacy and tolerability of intralesional bleomycin in dermatology: a systematic review","volume":"83","author":"Bik","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib117","series-title":"StatPearls","article-title":"Methotrexate","author":"Hanoodi","year":"2023"},{"issue":"7","key":"10.1016\/j.jaad.2024.10.130_bib118","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/DSS.0000000000001739","article-title":"Management of keratoacanthoma: 157 tumors treated with surgery or intralesional methotrexate","volume":"45","author":"Moss","year":"2019","journal-title":"Dermatol Surg"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib119","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaad.2006.12.017","article-title":"Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature","volume":"56","author":"Annest","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib120","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2020.03.096","article-title":"Intralesional methotrexate for keratoacanthomas: a retrospective cohort study","volume":"83","author":"Smith","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib121","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12872","article-title":"Intralesional therapy for the treatment of keratoacanthoma","volume":"32","author":"Kiss","year":"2019","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib122","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/life13061310","article-title":"The immunotherapeutic role of type I and III interferons in melanoma and non-melanoma skin cancers","volume":"13","author":"Weir","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.jaad.2024.10.130_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/847545","article-title":"Type I interferons: key players in normal skin and select cutaneous malignancies","volume":"2014","author":"Ismail","year":"2014","journal-title":"Dermatol Res Pract"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib124","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jaad.2009.12.013","article-title":"Intralesional agents in the management of cutaneous malignancy: a review","volume":"64","author":"Good","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.10.130_bib125","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/14737140.2023.2219449","article-title":"Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial","volume":"23","author":"Maleki","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib126","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1346-8138.1996.tb04040.x","article-title":"Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma","volume":"23","author":"Alpsoy","year":"1996","journal-title":"J Dermatol"},{"issue":"25","key":"10.1016\/j.jaad.2024.10.130_bib127","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jaad.2024.10.130_bib128","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e21583","article-title":"A single arm phase 2 study of talimogene laherparepvec in patients with low-risk invasive cutaneous squamous cell cancer. interim analysis","volume":"40","author":"Curiel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib129","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers"},{"issue":"15_suppl","key":"10.1016\/j.jaad.2024.10.130_bib130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e22050","article-title":"An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: initial results from the skin cancer cohorts","volume":"38","author":"Middleton","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib131","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib132","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1001\/jamadermatol.2018.3958","article-title":"Economic evaluation of talimogene laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma","volume":"155","author":"Almutairi","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.10.130_bib133","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s13555-023-00989-x","article-title":"Recommendations for cost-conscious treatment of basal cell carcinoma","volume":"13","author":"Patel","year":"2023","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib134","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2310\/7750.2008.07033","article-title":"Cost comparisons of managing complex facial basal cell carcinoma: Canadian study","volume":"12","author":"Lear","year":"2008","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2008.07.047","article-title":"A relative value unit\u2013based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption","volume":"61","author":"Rogers","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib136","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2021.05.058","article-title":"The role of radiation therapy in the management of cutaneous malignancies. Part I: diagnostic modalities and applications","volume":"85","author":"Wilmas","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib137","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaad.2021.05.057","article-title":"The role of radiation therapy in the management of cutaneous malignancies. Part II: when is radiation therapy indicated?","volume":"85","author":"Wilmas","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib138","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/cncr.22509","article-title":"What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion?","volume":"109","author":"Han","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib139","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40257-021-00615-6","article-title":"Review of perineural invasion in keratinocyte carcinomas","volume":"22","author":"Zhou","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib140","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0360-3016(01)01656-X","article-title":"Radiotherapy for epithelial skin cancer","volume":"51","author":"Locke","year":"2001","journal-title":"Int J Radiat Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib141","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/jamadermatol.2020.4931","article-title":"Changes in use of radiotherapy among dermatologists from 2013 to 2017","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib142","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/RLU.0000000000004824","article-title":"Topical 188Re ionizing radiation therapy exerts high efficacy in curing nonmelanoma skin cancer","volume":"48","author":"Tietze","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"23","key":"10.1016\/j.jaad.2024.10.130_bib143","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib144","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaad.2018.07.004","article-title":"Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: a systematic review and meta-analysis","volume":"79","author":"Xie","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib145","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2024.10.130_bib146","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.2013.49.9525","article-title":"Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma","volume":"32","author":"Kim","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib147","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2024.10.130_bib148","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002757","article-title":"Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis","volume":"9","author":"Rischin","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib149","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2015.11.007","article-title":"Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma","volume":"2","author":"Mohan","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib150","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.jaad.2024.10.130_bib151","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1002\/cncr.34463","article-title":"A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma","volume":"128","author":"Munhoz","year":"2022","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.jaad.2024.10.130_bib152","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib153","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdu368","article-title":"Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma","volume":"25","author":"Foote","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib154","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2017.07.048","article-title":"Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial","volume":"77","author":"William","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib155","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.31346","article-title":"Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"124","author":"Gold","year":"2018","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jaad.2024.10.130_bib156","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clon.2019.08.011","article-title":"Evolving role of systemic therapies in non-melanoma skin cancer","volume":"31","author":"Conforti","year":"2019","journal-title":"Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib157","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.drudis.2021.12.005","article-title":"The Hedgehog pathway and its inhibitors: emerging therapeutic approaches for basal cell carcinoma","volume":"27","author":"Jain","year":"2022","journal-title":"Drug Discov Today"},{"issue":"23","key":"10.1016\/j.jaad.2024.10.130_bib158","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jaad.2024.10.130_bib159","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.3390\/cancers13225706","article-title":"Treatment of advanced basal cell carcinoma with hedgehog pathway inhibitors: a multidisciplinary expert meeting","volume":"13","author":"De Giorgi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jaad.2024.10.130_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100844","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study)","volume":"35","author":"Bertrand","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib161","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-017-0319-4","article-title":"Small molecule inhibitors of the hedgehog pathway in the treatment of basal cell carcinoma of the skin","volume":"19","author":"Danhof","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2024.10.130_bib162","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/archdermatol.2012.2354","article-title":"Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma","volume":"148","author":"Chang","year":"2012","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib163","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ccell.2015.02.002","article-title":"Smoothened variants explain the majority of drug resistance in basal cell carcinoma","volume":"27","author":"Atwood","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib164","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jdcr.2017.11.011","article-title":"Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: clinical approach and genetic analysis","volume":"4","author":"Sinx","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/fon-2016-0296","article-title":"Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma","volume":"13","author":"Fife","year":"2017","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib166","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14656566.2022.2050215","article-title":"Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?","volume":"23","author":"Zhu","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaad.2024.10.130_bib167","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jdcr.2020.11.014","article-title":"Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma","volume":"7","author":"Yoon","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib168","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjd.19501","article-title":"How to break resistance to hedgehog inhibitors in advanced basal cell carcinoma?","volume":"184","author":"Ramelyte","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib169","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jdcr.2017.11.001","article-title":"Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib","volume":"4","author":"Yoon","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib171","doi-asserted-by":"crossref","DOI":"10.1111\/srt.13229","article-title":"Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: a systemic review and meta-analysis","volume":"29","author":"Zhang","year":"2023","journal-title":"Skin Res Technol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib172","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2024.10.130_bib173","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.annonc.2023.10.123","article-title":"Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors","volume":"35","author":"Lewis","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib174","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/jamaoncol.2023.0147","article-title":"Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate 714 randomized clinical trial","volume":"9","author":"Harrington","year":"2023","journal-title":"JAMA Oncol"},{"issue":"S1","key":"10.1016\/j.jaad.2024.10.130_bib175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jdv.17402","article-title":"Management of immune-related adverse events in anti-PD-1-treated patients with advanced cutaneous squamous cell carcinoma","volume":"36","author":"Gambichler","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib176","doi-asserted-by":"crossref","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.jaad.2024.10.130_bib177","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jamaoncol.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 Years or older with cancer: a multicenter international cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib178","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40266-019-00697-2","article-title":"Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer","volume":"36","author":"Van Holstein","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jaad.2024.10.130_bib179","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: part 2. Treatment\u2013update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib180","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/bjd.14936","article-title":"Epidermal growth factor receptor expression is associated with poor outcome in cutaneous squamous cell carcinoma","volume":"176","author":"Ca\u00f1ueto","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib181","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib182","doi-asserted-by":"crossref","first-page":"709","DOI":"10.18632\/oncotarget.28470","article-title":"Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series","volume":"14","author":"Chang","year":"2023","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib183","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18632\/oncotarget.27434","article-title":"Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study","volume":"11","author":"Montaudi\u00e9","year":"2020","journal-title":"Oncotarget"},{"issue":"05","key":"10.1016\/j.jaad.2024.10.130_bib184","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-0033-1353377","article-title":"Chemoprevention of nonmelanoma skin cancer","volume":"29","author":"Soltani-Arabshahi","year":"2013","journal-title":"Facial Plast Surg"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib185","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2022.11.044","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib186","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib187","doi-asserted-by":"crossref","first-page":"247","DOI":"10.14740\/jocmr3744","article-title":"Association between the use of thiazide diuretics and the risk of skin cancers: a meta-analysis of observational studies","volume":"11","author":"Shin","year":"2019","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.jaad.2024.10.130_bib188","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdin.2023.04.007","article-title":"Hydrochlorothiazide increases risk of nonmelanoma skin cancer in an elderly Japanese cohort with hypertension: the Shizuoka study","volume":"12","author":"Hashizume","year":"2023","journal-title":"JAAD Int"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib189","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jaad.2017.06.032","article-title":"Effect of voriconazole on risk of nonmelanoma skin cancer after hematopoietic cell transplantation","volume":"77","author":"Kuklinski","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.10.130_bib190","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jamadermatol.2020.1141","article-title":"Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States","volume":"156","author":"D'Arcy","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib191","series-title":"StatPearls","article-title":"Acitretin","author":"Zito","year":"2023"},{"issue":"8","key":"10.1016\/j.jaad.2024.10.130_bib192","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","article-title":"Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study","volume":"13","author":"Bavinck","year":"1995","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib193","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/archderm.141.4.456","article-title":"Low-dose Retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study","volume":"141","author":"Harwood","year":"2005","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2024.10.130_bib194","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1440-0960.2002.00613.x","article-title":"Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients","volume":"43","author":"George","year":"2002","journal-title":"Australas J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2024.10.130_bib195","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/DSS.0000000000002072","article-title":"Use of topical and systemic retinoids in solid organ transplant recipients: update and review of the current literature","volume":"45","author":"Herold","year":"2019","journal-title":"Dermatol Surg"},{"issue":"11","key":"10.1016\/j.jaad.2024.10.130_bib196","first-page":"957","article-title":"Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group","volume":"6","author":"Levine","year":"1997","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.jaad.2024.10.130_bib197","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/jnci\/84.5.328","article-title":"Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial","volume":"84","author":"Tangrea","year":"1992","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib198","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1940-6207.CAPR-13-0305","article-title":"Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome","volume":"7","author":"Tang","year":"2014","journal-title":"Cancer Prev Res"},{"issue":"6","key":"10.1016\/j.jaad.2024.10.130_bib199","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/jid.2011.483","article-title":"Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial","volume":"132","author":"Weinstock","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.10.130_bib200","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMoa2203086","article-title":"Nicotinamide for skin-cancer chemoprevention in transplant recipients","volume":"388","author":"Allen","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jaad.2024.10.130_bib201","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib202","first-page":"148","article-title":"Role of oral polypodium leucotomos extract in dermatologic diseases: a review of the literature","volume":"13","author":"Choudhry","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.10.130_bib203","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamadermatol.2017.3631","article-title":"Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial","volume":"154","author":"Weinstock","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2024.10.130_bib204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/860479","article-title":"The role of antioxidants in skin cancer prevention and treatment","volume":"2014","author":"Godic","year":"2014","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jaad.2024.10.130_bib205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/893149","article-title":"Diet and skin cancer: the potential role of dietary antioxidants in nonmelanoma skin cancer prevention","volume":"2015","author":"Katta","year":"2015","journal-title":"J Skin Cancer"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib206","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamadermatol.2021.3019","article-title":"Clinical evidence on \u201cwatchful waiting\u201d in basal cell carcinoma","volume":"157","author":"Wehner","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib207","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/prd.12126","article-title":"The aging population: demographics and the biology of aging","volume":"72","author":"Kanasi","year":"2016","journal-title":"Periodontol 2000"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib208","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/jgs.17011","article-title":"Heterogeneity of aging: individual risk factors, mechanisms, patient priorities, and outcomes","volume":"69","author":"Ferrucci","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"10.1016\/j.jaad.2024.10.130_bib209","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jamainternmed.2021.2643","article-title":"Active surveillance as a management option for low-risk basal cell carcinoma","volume":"181","author":"Linos","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.jaad.2024.10.130_bib210","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamadermatol.2021.3020","article-title":"Evaluation of watchful waiting and tumor behavior in patients with basal cell carcinoma: an observational cohort study of 280 basal cell carcinomas in 89 patients","volume":"157","author":"Van Winden","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.10.130_bib211","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.16730","article-title":"Natural history of lesions suspicious for basal cell carcinoma in older adults in Ikaria, Greece","volume":"179","author":"Wehner","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2024.10.130_bib212","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-0560.2009.01340.x","article-title":"Recurrence rates associated with incompletely excised low-risk nonmelanoma skin cancer","volume":"37","author":"Rieger","year":"2010","journal-title":"J Cutan Pathol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225003202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225003202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:44:51Z","timestamp":1793598291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225003202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":212,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0190962225003202"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.10.130","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimally invasive modalities for keratinocyte carcinomas \u2014Part II: Treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.10.130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(26)02684-8","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.02.036","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}